HeartBeam, Inc. · NASDAQ:BEAT

HeartBeam — Q3 2026 Earnings Presentation

19 slides from HeartBeam's earnings presentation, Nov 12, 2026

  1. Slide 1: Total Heart Intelligence… Wherever You Are

    Total Heart Intelligence… Wherever You Are THIRD QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL NOVEMBER 12, 2026 NASDAQ: BEAT

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, regulatory and clinic

  3. Slide 3: Agenda

    Agenda WHAT WE'LL COVER ON THE CALL TODAY 1 Progress on Key Strategic Priorities RICHARD FERRARI Executive Chairman 2 HeartBeam’s Cardiac Platform Opportunity DR. BRANISLAV VAJDIC President & Founder 3 Heart Attack Detection: Significant Milestones Achieved TIM CRUICKSHANK 4 Financials Chief Financi

  4. Slide 4: Progress on Key Strategic Priorities

    Progress on Key Strategic Priorities Heart Attack Detection is our top strategic priority. Clinical and Regulatory initiatives are rapidly advancing. HEART ATTACK DETECTION UNLOCKING PAYMENT LONG-TERM VALUE & AI FINANCIALS & COST PATHWAYS PROFILE • Significant milestones • Building supporting data f

  5. Slide 5: HeartBeam's Cardiac Platform Opportunity

    HeartBeam’s Cardiac Platform Opportunity Third Quarter 2026 Financial Results Conference Call 5

  6. Slide 6: Patient Delay is the Major Driver Behind the #1 Cause of Death

    Patient Delay is the Major Driver Behind the #1 Cause of Death Treatment time in hospital is optimized. Patient delay happens before arrival. SYMPTOM-TO-DOOR DOOR-TO-BALLOON Optimized, in guidelines Patients Delay 2+ Hours Treatment Time is Optimized Once Before Taking Action1 the Patient Reaches th

  7. Slide 7: HeartBeam's Core Technology and Platform

    HeartBeam’s Core Technology and Platform Why HeartBeam Is Fundamentally Different Cardiac Platform Opportunity CARDIAC PLATFORM OPPORTUNITY i • Closes the gap between symptom onset and care by giving • patients a clinical grade ECG wherever they are, at the moment symptoms occur. First-of-its-kind,

  8. Slide 8: One platform. Multiple form factors.

    CORE PLATFORM One platform. Multiple form PATENTED 3D 3L SIGNAL factors. COLLECTION TECHNOLOGY Shared cardiac intelligence. FORM FACTORS HEARTBEAM 12-LEAD PATCH HEARTBEAM SYSTEM* CONTINUOUS 1-LEAD → REMOTE UNIT CABLE-FREE 12-LEAD ECG 12-LEAD ON DEMAND PRIMARY APPLICATION FOR AT-HOME USE OUTSIDE THE

  9. Slide 9: Heart Attack Detection: Significant Milestones Achieved

    Heart Attack Detection: Significant Milestones Achieved Third Quarter 2026 Financial Results Conference Call 9

  10. Slide 10: Heart Attack Assessment: Regulatory Roadmap

    Heart Attack Assessment: Regulatory Roadmap Accelerating the Path to FDA Clearance Positive Pilot Study Alignment with FDA Alignment with FDA Commence U.S. U.S. Pivotal Study FDA Clearance Data on 510(k) Pathway on U.S. Pivotal Study Pivotal Study Enrollment Design Complete CONTINUED COMPLETED EXPEC

  11. Slide 11: ALIGN-ACS Pilot Study: Positive Results Presented at TCT 2026

    ALIGN-ACS Pilot Study: Positive Results Presented at TCT 2026 Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG ACS detection: HeartBeam vs. standard 12-lead ECG (%) Our HeartBeam 3D 3-lead and the 12-lead 81.8% 0.73 showed same Area Under the Curve (AUC), implying identical in

  12. Slide 12: Expanding Body of Clinical Evidence for Heart Attack Assessment

    Expanding Body of Clinical Evidence for Heart Attack Assessment ALIGN-ACS Pilot Study · Completed 132 patients across two emergency departments in Belgrade, Serbia. Positive results presented at TCT 2026. 600+ HEADSTART-ACS · Enrollment complete; data analysis underway 486 patients at Harapan Kita N

  13. Slide 13: Payment Pathways Evolving for Novel Cardiac Technologies

    Payment Pathways Evolving for Novel Cardiac Technologies Building the real-world evidence and data collection we need to support our reimbursement strategy 1 2 3 Direct access to CMS and New and existing CPT codes Building supporting data for payors symptom-to-door time TAP Pilot acceptance connects

  14. Slide 14: AI Program: Building on the 3D ECG Platform

    AI Program: Building on the 3D ECG Platform Encouraging internal results; first peer-reviewed manuscript accepted AI DATASETS PUBLICATIONS ECGs for heart HeartBeam device 168,000+ attack training 2,100+ recordings for testing Atrial flutter AI algorithm EHRA 2026 abstract (EP Europace); manuscript a

  15. Slide 15: Financials

    Financials Third Quarter 2026 Financial Results Conference Call 15

  16. Slide 16: Capital Efficiency Through Focused Path to Heart Attack Detection

    Capital Efficiency Through Focused Path to Heart Attack Detection Total operating expenses, Q3 2026 Total operating expenses by quarter ($M) Net cash used in operating activities by $3.5M ▼ 32% vs. Q2 2026 quarter ($M) ▼ 35% vs. Q3 2025 $5.3M $5.3M $5.1M $4.7M $3.6M $3.3M $3.2M Net cash used in oper

  17. Slide 17: Third Quarter and Year-to-Date Results

    Third Quarter and Year-to-Date Results QUARTER ENDED NINE MONTHS ENDED $ in thousands Sep 30, 2026ⁱ Jun 30, 2026 Sep 30, 2025 Sep 30, 2026ⁱ Sep 30, 2025 Selling, general & administrative 1,339 2,764 2,012 6,449 5,733 Research & development 2,118 2,328 3,278 6,816 10,096 Total operating expenses 3,45

  18. Slide 18: Summary: Key Takeaways

    Summary: Key Takeaways Heart Attack Detection is our top strategic priority A massive opportunity within a $40B cardiac platform market, and we have the product, IP, and team to pursue it SIGNIFICANT PROGRESS MADE PATH TO PAYMENT EXECUTION PLAY Recent milestones are the evidence Payment pathways evo

  19. Slide 19: Redefining Cardiac Care Q&A

    Redefining Company Tim Cruickshank Investor Relations Chris Tyson NASDAQ: BEAT Cardiac Care CFO HeartBeam, Inc. Executive Vice President MZ North America Anytime, Anywhere. ir@heartbeam.com Direct: 949-491-8235 www.heartbeam.com BEAT@mzgroup.us www.mzgroup.us Q&A HeartBeam System is FDA-cleared for

HeartBeam — Q3 2026 Earnings Presentation on 6ix